- Home
- SMTC vs SRRK Comparison
SMTC vs SRRK Comparison
Compare SMTC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTC
- SRRK
- Stock Information
- Founded
- SMTC 1960
- SRRK 2012
- Country
- SMTC United States
- SRRK United States
- Employees
- SMTC N/A
- SRRK N/A
- Industry
- SMTC Semiconductors
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMTC Technology
- SRRK Health Care
- Exchange
- SMTC Nasdaq
- SRRK Nasdaq
- Market Cap
- SMTC 3.3B
- SRRK 4.2B
- IPO Year
- SMTC N/A
- SRRK 2018
- Fundamental
- Price
- SMTC $32.71
- SRRK $34.55
- Analyst Decision
- SMTC Strong Buy
- SRRK Strong Buy
- Analyst Count
- SMTC 12
- SRRK 7
- Target Price
- SMTC $67.91
- SRRK $40.43
- AVG Volume (30 Days)
- SMTC 2.5M
- SRRK 786.7K
- Earning Date
- SMTC 03-13-2025
- SRRK 05-06-2025
- Dividend Yield
- SMTC N/A
- SRRK N/A
- EPS Growth
- SMTC N/A
- SRRK N/A
- EPS
- SMTC N/A
- SRRK N/A
- Revenue
- SMTC $851,233,000.00
- SRRK N/A
- Revenue This Year
- SMTC $6.56
- SRRK N/A
- Revenue Next Year
- SMTC $17.74
- SRRK $599.61
- P/E Ratio
- SMTC N/A
- SRRK N/A
- Revenue Growth
- SMTC 0.94
- SRRK N/A
- 52 Week Low
- SMTC $21.56
- SRRK $6.76
- 52 Week High
- SMTC $79.52
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- SMTC 35.72
- SRRK 39.37
- Support Level
- SMTC $29.98
- SRRK $34.14
- Resistance Level
- SMTC $34.31
- SRRK $37.30
- Average True Range (ATR)
- SMTC 2.74
- SRRK 2.16
- MACD
- SMTC 0.62
- SRRK -0.07
- Stochastic Oscillator
- SMTC 28.09
- SRRK 7.50
About SMTC Semtech Corporation
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments' 1) Signal Integrity, 2) Advanced Protection and Sensing, 3) IoT System and 4) IoT Connected Services. The majority of the company's revenue is earned through Advanced Protection and Sensing Products segment. Geographically majority of the company's revenue is earned from Asia Pacific region.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.